🔗 Visit the ClinicalTrials.gov page for NCT02407054
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. | Clin Med Insights Oncol | 2016 | 0.83 |
| 2 | New drugs in prostate cancer. | Prostate Int | 2016 | 0.80 |
| 3 | CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. | Ther Adv Med Oncol | 2016 | 0.77 |
| 4 | Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer. | Curr Urol Rep | 2016 | 0.77 |
| 5 | Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer. | Oncotarget | 2015 | 0.77 |
| 6 | Androgen pathway resistance in prostate cancer and therapeutic implications. | Expert Opin Pharmacother | 2015 | 0.77 |